Abstract:
:Calcitonin gene-related peptide (CGRP) is a signaling neuropeptide released from activated trigeminal sensory afferents in headache and facial pain disorders. There are a handful of CGRP-targeted therapies currently in phase 3 studies for migraine acute treatment or prevention. Currently, 4 monoclonal antibodies targeting either the CGRP ligand or receptor are being studied for migraine prevention: ALD403 (eptinezumab), AMG 334 (erenumab), LY2951742 (galcanezumab), and TEV-48125 (fremanezumab). Meanwhile, 1 small-molecule CGRP receptor antagonist (ubrogepant, MK-1602) is currently in phase 3 studies for the acute treatment of migraine. Two of these anti-CGRP monoclonal antibodies are in clinical trials for cluster headache prevention as well. Several other small-molecular CGRP receptor antagonists are in earlier stages of development for acute migraine treatment or prevention. In this review, we will discuss the growing body of clinical trials studying CGRP-targeted therapies for migraine and cluster headache.
journal_name
Clin Neuropharmacoljournal_title
Clinical neuropharmacologyauthors
Schuster NM,Rapoport AMdoi
10.1097/WNF.0000000000000227subject
Has Abstractpub_date
2017-07-01 00:00:00pages
169-174issue
4eissn
0362-5664issn
1537-162Xjournal_volume
40pub_type
杂志文章,评审abstract::Glutamate is the predominant excitatory neurotransmitter of the basal ganglia, where it acts on ionotropic and metabotropic receptors. In the best studied of the basal ganglia disorders, Parkinson's disease, there is compelling evidence that the activities of glutamatergic pathways are altered. Of particular importanc...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/00002826-200103000-00001
更新日期:2001-03-01 00:00:00
abstract::This study reports the antidepressant efficacy and the safety of amineptine (Survector 100) in a national multicenter open clinical trial (32 hospital centers). Three hundred twenty-four patients with depressive disorders, selected according to DSM-III Diagnostic Criteria and INSERM classification, were treated with a...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1097/00002826-198912002-00006
更新日期:1989-01-01 00:00:00
abstract::Clinical trials with cholinergic agents suggest that cholinergic hypertrophy may be beneficial in the treatment of Alzheimer's disease (AD). Recent findings substantiate the view that nerve growth factor (NGF) selectively acts on cholinergic neurons. In adult rats and primates, intraventricular administration of nerve...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/00002826-199114001-00008
更新日期:1991-01-01 00:00:00
abstract::A matter of debate is the impact of levodopa (LD) application in patients with Parkinson disease (PD) on altered force development and coordination, which are also influenced by the strength of muscles used. The objectives were to compare the motor response, the development of grip strength, and the pharmacokinetic be...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0b013e31811510ed
更新日期:2008-05-01 00:00:00
abstract::Preclamol, the (-)enantiomer of 3-PPP (= 3(3-hydroxyphenyl)-N-n-propyl piperidine), has a selective dopamine autoreceptor- and postsynaptic mixed agonist-antagonist profile. Its action on patients with disabling on-off parkinsonian fluctuations has been studied and compared with those of placebo and subcutaneous apomo...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:
更新日期:1993-12-01 00:00:00
abstract::Two patients with essential tremor who had no psychiatric history developed symptoms of psychosis (visual hallucinations, paranoia, and vivid dreams) 3 days after starting topiramate (25 mg BID) for tremor control. All adverse symptoms resolved several days after topiramate was discontinued. ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/01.WNF.0000220823.80640.44
更新日期:2006-05-01 00:00:00
abstract::Neuroleptic-induced tardive dyskinesia (TD) that persists for 1 year or more following withdrawal of neuroleptics is usually said to be permanent. Early spontaneous remissions have been well described but most such remissions occurred within the first few months following neuroleptic withdrawal, and no published studi...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-198406000-00006
更新日期:1984-01-01 00:00:00
abstract:OBJECTIVE:To review the current evidence on the effectiveness of second-generation antipsychotics (SGAs) in the treatment of tardive dystonia (TDt) and give recommendations for treatment. METHODS:Medline/PubMed/Psyclit/Embase database searches were conducted in January 2015, and a manual review of references within th...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/WNF.0000000000000106
更新日期:2015-09-01 00:00:00
abstract::In this study, the hemodynamic and neurochemical effects of lisuride, a dopamine agonist with serotoninergic properties, have been evaluated in de novo parkinsonian patients and in elderly subjects with mild cognitive impairment. Blood pressure (BP), heart rate (HR), and urinary catecholamine (CA) fluctuations through...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-198910000-00005
更新日期:1989-10-01 00:00:00
abstract:OBJECTIVE:We present 3 new cases of psychotic symptoms in patients with adult attention-deficit/hyperactivity disorder while regularly treated with a stimulant therapy with methylphenidate. METHODS:Existing literature about this theme is reviewed, and potential mechanisms are discussed. RESULTS AND CONCLUSIONS:Medica...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/WNF.0b013e3181e29174
更新日期:2010-07-01 00:00:00
abstract::Several recent reports attest to zolpidem's strong potential for abuse, dependence, and severe withdrawal symptoms upon its discontinuation. We report, for the first time, on 1 case of heavy zolpidem abuse and dependence with severe withdrawal symptoms twice treated safely and successfully with pregabalin, a newer ant...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0b013e31820a3b5a
更新日期:2011-03-01 00:00:00
abstract::Modafinil is a psychostimulant compound that is just now becoming available in many countries for treatment of narcoleptic and hypersomnic patients. Whereas sleep attacks and drowsiness can be effectively improved, the drug does not sufficiently reduce cataplectic seizures. It therefore is often used in combination wi...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:
更新日期:1998-03-01 00:00:00
abstract:OBJECTIVES:We investigated the effects of age on the association between early and eventual responses to paroxetine treatment in patients with major depressive disorder (MDD). METHODS:Eighty-nine patients with MDD were administered paroxetine and completed the 6-week protocol. On the basis of our previous study, we de...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000058
更新日期:2015-01-01 00:00:00
abstract::We studied a 67-year-old woman with a sporadic form of hyperekplexia, who experienced 8-10 excessive startle responses to unexpected stimuli per month. Therapy with fluoxetine had a definite beneficial effect. This finding supports the hypothesis that serotonergic mechanisms play a role in this disorder. ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-200005000-00006
更新日期:2000-05-01 00:00:00
abstract::We studied the effectiveness of OR-611 and OR-462, two novel inhibitors of the enzyme catechol-O-methyltransferase (COMT), on 3-O-methyldopa (OMD) formation in cynomolgus monkeys following intravenous levodopa administration. OR-611 dose-dependently reduced the area under the OMD concentration-vs-time curve, reduced m...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199108000-00005
更新日期:1991-08-01 00:00:00
abstract::The capacity of peripheral blood mononuclear cells (PBMCs) of anorexia nervosa (AN) patients to produce interleukin-1 (IL-1), interleukin-2 (IL-2), and interleukin-3-like activity (IL-3-LA) was studied. A significantly lower (-49%, p < 0.005) capacity to synthesize IL-2 and an almost significantly impaired ability (-3...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199306000-00007
更新日期:1993-06-01 00:00:00
abstract::The standard therapy for myasthenia gravis (MG) includes steroids and immunosuppressants, which have delayed onset of action and significant side effects. Plasmapheresis and intravenous immunoglobulin have been used mostly for the treatment of severe exacerbations. In the present study we examined the use of intraveno...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-200105000-00010
更新日期:2001-05-01 00:00:00
abstract::We studied the effect of inhibiting the enzyme catechol-O-methyltransferase (COMT) by a novel COMT inhibitor, entacapone, on the pharmacokinetics and metabolism of levodopa in 12 healthy male volunteers. Single increasing oral doses of entacapone (50-400 mg) were administered concomitantly with a single oral dose of l...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199304000-00007
更新日期:1993-04-01 00:00:00
abstract::Adjunctive use of methylphenidate, a central stimulant, has been considered as a potential therapeutic choice for patients with refractory unipolar depression, geriatric depression, bipolar depression, and depression secondary to a medical illness. We present a case of psychotic unipolar depression in which the patien...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0b013e318157d998
更新日期:2008-07-01 00:00:00
abstract::Successful combination therapy with atypical antipsychotics and selective serotonin reuptake inhibitors has been reported for several psychiatric conditions. However, great attention should be paid to the possible adverse effects. In this retrospective chart review, we focused on the drug-drug interaction of paroxetin...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-200209000-00009
更新日期:2002-09-01 00:00:00
abstract::This study was devised to check the feasibility and validity of a rating scale specifically designed to evaluate gait impairment in Parkinson's disease (RSGE). Demographic data, a brief questionnaire on general aspects influencing gait and mobility, a battery of scales (Barthel Index; Hoehn and Yahr staging; and North...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,多中心研究
doi:10.1097/00002826-199706000-00001
更新日期:1997-06-01 00:00:00
abstract::Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder. This disorder was characterized by aggressive agitation, self injurious behavior, insomnia, and incessant motor activity occurring between 10 and 55 days after initiation of drug therapy. The affected c...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-199408000-00004
更新日期:1994-08-01 00:00:00
abstract::Prion diseases are invariably fatal. Recently, quinacrine and chlorpromazine have been suggested as immediate candidates for the treatment of Creutzfeldt-Jakob disease and other prion diseases. The objective of this paper was to report on 2 fatal familial insomnia patients whose overall condition worsened despite quin...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/01.wnf.0000134853.36429.0e
更新日期:2004-07-01 00:00:00
abstract::To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (> 5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cra...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-200001000-00008
更新日期:2000-01-01 00:00:00
abstract::Palinopsia is an illusory visual phenomenon consisting in the persistence or recurrence of visual images after the exciting stimulus object has been removed. It has been reported in association with parietal and occipital lobe lesions, migraine auras, and related to the use of several drugs and illicit drugs. Here, we...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/WNF.0b013e3182849208
更新日期:2013-03-01 00:00:00
abstract::The main augmentation strategy in the treatment of obsessive-compulsive disorder (OCD) is the addition of low-dose dopamine antagonists, such as risperidone. However, the development of additional pharmacological therapeutics is necessary because some patients remain refractory to these strategies. In the present repo...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0b013e318223421f
更新日期:2011-07-01 00:00:00
abstract::Botulinum toxin A (BTA) is considered an effective treatment of cervical dystonia. The aim of this prospective, randomized, double-blind study was to compare Botox and Prosigne, a BTA of Chinese origin, with a view to establish the safety, the efficacy, and the equivalence of doses of the 2 formulations in the treatme...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/WNF.0b013e3181c46f48
更新日期:2010-01-01 00:00:00
abstract::Twelve-hour urinary excretion of 4-hydroxy-3-methoxymandelic acid (VMA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) was studied in 20 premature infants, 8 without apnea and 12 with apnea. All infants were studied at 1-3 days of postnatal age (before apnea). Nonapneic infants were restudied at ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-198212000-00006
更新日期:1982-12-01 00:00:00
abstract::Hypersialorrhea is frequently reported in patients with idiopathic Parkinson's Disease (PD). Excessive production of saliva, swallowing difficulties, or both could explain this complaint. Dopamine (DA) has been shown to modulate salivary secretion in a number of vertebrate and invertebrate species. The present study w...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:
更新日期:1999-07-01 00:00:00
abstract:BACKGROUND:We investigated the frequencies of the symptoms such as "ataxia, depression, insomnia, anorexia, and pain," that have been reported to be associated with 5-HT1A receptor, and the effect of tandospirone citrate (tandospirone: 5-HT1A agonist) in patients with Machado-Joseph disease (MJD). METHODS:Ten MJD pati...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-200401000-00005
更新日期:2004-01-01 00:00:00